VivoSeq
Ophthalmology

Ptosis

14

Pipeline Programs↗

6

Active Trials↗

11

Companies Involved↗

Ptosis is an emerging landscape with 14 programs across 11 companies. The most active players are Levation Pharma, Ltd., Pfizer, Roche. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

10/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Levation Pharma, Ltd.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Roche logo

Roche

2 programs

Phase 2F

Fresenius Kabi Oncology Ltd.

2 programs

Phase 2AbbVie logo

AbbVie

2 programs

Phase 2S

Santen Pharmaceutical Co., Ltd.

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

18 of 21 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody314%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed12 · 57%
Recruiting4 · 19%
Unknown status3 · 14%
Not yet recruiting2 · 10%

Clinical Trials

Trial Activity

21 trials

A Study in Chinese Patients With Acquired Blepharoptosis
Recruiting·SSanten Pharmaceutical Co., Ltd.·Phase 3·NCT06683651·180 enrolled
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
Recruiting·SSanten Inc.·Phase 3·NCT06514612·234 enrolled
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Recruiting·—·Phase 1·NCT07433621·12 enrolled
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
Recruiting·UUniversity of Aarhus·Phase 1/2·NCT05668026·18 enrolled
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir: An Investigator-initiated Randomised, Controlled, Open-label Clinical Trial (The INITIATE Study)
Not yet recruiting·—·Phase 1·NCT07481175·38 enrolled
Upneeq vs. Lumify Ptosis
Not yet recruiting·—·Phase 4·NCT07390578·50 enrolled
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
Completed·FFondazione Michelangelo·Phase 2·NCT02530424·102 enrolled
Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
Completed·UUniversity of Athens·N/A·NCT01000337·67 enrolled
Anesthesia and Lymphocytes Apoptosis
Completed·RRuijin Hospital·N/A·NCT01461551·105 enrolled
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Completed·RRVL Pharmaceuticals, Inc.·Phase 3·NCT02436759·140 enrolled
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Completed·RRVL Pharmaceuticals, Inc.·Phase 3·NCT03536949·234 enrolled
Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa
Completed·SS.L.A. Pharma AG·Phase 2/3·NCT00432913·120 enrolled
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
Completed·Amgen logoAmgen·Phase 3·NCT03461211·51 enrolled
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Completed·RRVL Pharmaceuticals, Inc.·Phase 3·NCT03565887·164 enrolled
Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
Completed·MMilton S. Hershey Medical Center·Phase 3·NCT05945615·36 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)